Nova Patents
GEP20105083B

A solid pharmaceutical dosage formulation

Abstract

The present invention provides a pharmace¬utical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

98 members in 39 offices

This recordMember, by publication datePriority claim29 more offices are in the list below

Priority claims1

Priority claims
DocumentOfficeKindDate
6446705United States of AmericaA

Members98

Family members, oldest first
DocumentOfficeKind
US2005084529A1United States of AmericaA1
US2005143404A1United States of AmericaA1
AU2006216856A1AustraliaA1
CA2598827A1CanadaA1
CA2821046A1CanadaA1
WO2006091529A2World Intellectual Property Organization (WIPO)A2
UY29391A1UruguayA1
PE20061016A1PeruA1
DOP2006000050ADominican RepublicA
SV2007002427AEl SalvadorA
WO2006091529A3World Intellectual Property Organization (WIPO)A3
TW200716119ATaiwan Province of ChinaA
AR055734A1ArgentinaA1
GT200600295AGuatemalaA
NO20074807LNorwayL
US2007249643A1United States of AmericaA1
MX2007010275AMexicoA
MX2007010275AMexicoA
EP1855683A2European Patent Office (EPO)A2
KR20070114294ARepublic of KoreaA
IL185390A0IsraelA0
EA200701790A1Eurasian Patent Organization (EAPO)A1
CR9353ACosta RicaA
CR9353ACosta RicaA
CN101163479AChinaA
JP2008531565AJapanA
US2008299203A1United States of AmericaA1
ZA200707022BSouth AfricaB
CL2009001844A1ChileA1
UA89220C2UkraineC2
BRPI0609173A2BrazilA2
PE20100123A1PeruA1
EP2206500A1European Patent Office (EPO)A1
GEP20105083BThis recordGeorgiaB
NZ560829ANew ZealandA
EA014446B1Eurasian Patent Organization (EAPO)B1
US2011008430A1United States of AmericaA1
US2011015216A1United States of AmericaA1
EP2283844A1European Patent Office (EPO)A1
UY32116AUruguayA
AR077411A2ArgentinaA2
US8025899B2United States of AmericaB2
CN101163479BChinaB
US2012022089A1United States of AmericaA1
AU2006216856B2AustraliaB2
GT200600295AAGuatemalaA
AU2012202831A1AustraliaA1
MY146247AMalaysiaA
US2012202858A1United States of AmericaA1
US8268349B2United States of AmericaB2
US8309613B2United States of AmericaB2
JP5087409B2JapanB2
US8333990B2United States of AmericaB2
US2013004578A1United States of AmericaA1
TWI381840BTaiwan Province of ChinaB
US8377952B2United States of AmericaB2
US8399015B2United States of AmericaB2
US2013072508A1United States of AmericaA1
CA2598827CCanadaC
PH12012501811A1PhilippinesA1
NZ599361ANew ZealandA
US8691878B2United States of AmericaB2
CL2013003554A1ChileA1
US2014179721A1United States of AmericaA1
KR101429024B1Republic of KoreaB1
AU2012202831B2AustraliaB2
BR122012031169A2BrazilA2
IL185390AIsraelA
EP2206500B1European Patent Office (EPO)B1
CA2821046CCanadaC
CL2017001847A1ChileA1
PT2206500TPortugalT
LT2206500TLithuaniaT
ES2675548T3SpainT3
DK2206500T3DenmarkT3
TR2018009084T4TürkiyeT4
TR201809084T4TürkiyeT4
EP2283844B1European Patent Office (EPO)B1
HRP20180999T1CroatiaT1
RS57378B1SerbiaB1
SI2206500T1SloveniaT1
HUE038073T2HungaryT2
PL2206500T3PolandT3
LT2283844TLithuaniaT
PT2283844TPortugalT
TR2018016268T4TürkiyeT4
TR201816268T4TürkiyeT4
DK2283844T3DenmarkT3
ES2694073T3SpainT3
SI2283844T1SloveniaT1
HRP20181819T1CroatiaT1
RS57938B1SerbiaB1
PL2283844T3PolandT3
EP3482762A1European Patent Office (EPO)A1
HUE041591T2HungaryT2
CY1120377T1CyprusT1
DOP2019000185ADominican RepublicA
CY1122777T1CyprusT1